Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Goldman Sachs raises Tesla's delivery and earnings-per-share forecasts, maintains Neutral rating and $375 target price

Goldman Sachs raises Tesla's delivery and earnings-per-share forecasts, maintains Neutral rating and $375 target price

AiCoinAiCoin2026/06/16 08:45
Show original
Goldman Sachs has raised its Tesla delivery forecast for Q2 2026 from 405,000 vehicles to 420,000 vehicles, surpassing the market consensus of 400,000 vehicles compiled by Visible Alpha. The full-year 2026 delivery forecast has also been increased from 1.72 million vehicles to 1.73 million vehicles. Goldman Sachs maintains its 2027 forecast at 1.88 million vehicles and 2028 at 1.96 million vehicles. In addition, the earnings per share estimate for 2026 has been increased from $1.30 to $1.35. Tesla's rating remains neutral with a target price of $375, presenting an 8.8% downside compared to the current share price of $411.15.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Sixth increase in six years! Disney(DIS.US) raises the monthly fee for Disney+ ad-free version by 13% to $21.49.

Walt Disney Company (DIS.US) is raising subscription prices for several of its streaming services in the U.S. market, marking the sixth price increase in six years, as the company aims to boost the profitability of its streaming business, which is crucial for Disney's future.

智通财经2026/09/24 06:51

Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth

On September 24, according to the CDE website, Johnson & Johnson’s (JNJ.US) talquetamab (Chinese brand name: Tuolike) is proposed to be included in priority review.

智通财经2026/09/24 06:51
Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth

Australian stocks closed down 0.72%

格隆汇2026/09/24 06:27